These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31436251)

  • 21. Predicting
    Miao L; Qiu T; Li Y; Li J; Jiang X; Liu M; Zhang X; Jiang J; Zhang H; Wang Y; Li X; Ying J; Li M
    Transl Lung Cancer Res; 2024 Jun; 13(6):1232-1246. PubMed ID: 38973946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
    Kneuertz PJ; Carbone DP; D'Souza DM; Shilo K; Abdel-Rasoul M; Zhao W; Williams TM; Jones D; Merritt RE
    Lung Cancer; 2020 May; 143():60-66. PubMed ID: 32208298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of MET Exon 14 Skipping Alterations in Lung Cancer Clinical Samples Using a PCR-Based Approach.
    Sui JSY; Finn SP; Gray SG
    Methods Mol Biol; 2021; 2279():145-155. PubMed ID: 33683691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.
    Saffroy R; Fallet V; Girard N; Mazieres J; Sibilot DM; Lantuejoul S; Rouquette I; Thivolet-Bejui F; Vieira T; Antoine M; Cadranel J; Lemoine A; Wislez M
    Oncotarget; 2017 Jun; 8(26):42428-42437. PubMed ID: 28418914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer.
    Xia Y; Jin R; Li M; Lan F; Zhu H; Yu Y; Miao D; Wang Q; Zhou Y; Selvaggi G; Ying S; Zhang J; Shen H; Le X; Li W
    Cancer Lett; 2023 May; 561():216140. PubMed ID: 36948240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival outcomes and prognostic factors of lung cancer patients with the
    Gow CH; Hsieh MS; Chen YL; Liu YN; Wu SG; Shih JY
    Front Oncol; 2023; 13():1113696. PubMed ID: 36969059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy.
    Hsieh MS; Lin MW; Lee YH
    Lung Cancer; 2019 Nov; 137():76-84. PubMed ID: 31561203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
    Wu YL; Smit EF; Bauer TM
    Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
    Suzawa K; Offin M; Lu D; Kurzatkowski C; Vojnic M; Smith RS; Sabari JK; Tai H; Mattar M; Khodos I; de Stanchina E; Rudin CM; Kris MG; Arcila ME; Lockwood WW; Drilon A; Ladanyi M; Somwar R
    Clin Cancer Res; 2019 Feb; 25(4):1248-1260. PubMed ID: 30352902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KRAS mutation is predictive of outcome in patients with pulmonary sarcomatoid carcinoma.
    Mehrad M; Roy S; LaFramboise WA; Petrosko P; Miller C; Incharoen P; Dacic S
    Histopathology; 2018 Aug; 73(2):207-214. PubMed ID: 29489023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.
    Wu C; Zhao C; Yang Y; He Y; Hou L; Li X; Gao G; Shi J; Ren S; Chu H; Zhou C; Zhang J; Schmid-Bindert G
    J Thorac Oncol; 2015 May; 10(5):778-783. PubMed ID: 25629635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
    Sabari JK; Leonardi GC; Shu CA; Umeton R; Montecalvo J; Ni A; Chen R; Dienstag J; Mrad C; Bergagnini I; Lai WV; Offin M; Arbour KC; Plodkowski AJ; Halpenny DF; Paik PK; Li BT; Riely GJ; Kris MG; Rudin CM; Sholl LM; Nishino M; Hellmann MD; Rekhtman N; Awad MM; Drilon A
    Ann Oncol; 2018 Oct; 29(10):2085-2091. PubMed ID: 30165371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies.
    Castiglione R; Alidousty C; Holz B; Wagener S; Baar T; Heydt C; Binot E; Zupp S; Kron A; Wolf J; Merkelbach-Bruse S; Reinhardt HC; Buettner R; Schultheis AM
    Mod Pathol; 2019 May; 32(5):627-638. PubMed ID: 30459450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
    Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
    J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
    Guo R; Berry LD; Aisner DL; Sheren J; Boyle T; Bunn PA; Johnson BE; Kwiatkowski DJ; Drilon A; Sholl LM; Kris MG
    J Thorac Oncol; 2019 Sep; 14(9):1666-1671. PubMed ID: 31228623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population.
    Lung J; Hung MS; Lin YC; Lee KF; Jiang YY; Huang SL; Fang YH; Lu MS; Lin CK; Yang TM; Lin PY; Hsieh MJ; Tsai YH
    PLoS One; 2019; 14(8):e0220670. PubMed ID: 31369639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
    Mazieres J; Vioix H; Pfeiffer BM; Campden RI; Chen Z; Heeg B; Cortot AB
    Clin Lung Cancer; 2023 Sep; 24(6):483-497. PubMed ID: 37451931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.
    Wong SK; Alex D; Bosdet I; Hughesman C; Karsan A; Yip S; Ho C
    Lung Cancer; 2021 Apr; 154():142-145. PubMed ID: 33667719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.
    Mignard X; Ruppert AM; Antoine M; Vasseur J; Girard N; Mazières J; Moro-Sibilot D; Fallet V; Rabbe N; Thivolet-Bejui F; Rouquette I; Lantuejoul S; Cortot A; Saffroy R; Cadranel J; Lemoine A; Wislez M
    J Thorac Oncol; 2018 Dec; 13(12):1962-1967. PubMed ID: 30149144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.